HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy - PubMed (original) (raw)

HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

Catalina Falo et al. J Cancer Res Clin Oncol. 2007 Jul.

Abstract

Purpose: Primary chemotherapy brings the opportunity for an early and accurate assessment of response and offers an ideal model to search for new predictors of response. HER-2/neu is one of the most studied genes for this purpose.

Patients and methods: Her-2/neu was tested in a non-randomized series of 300 patients with operable breast carcinomas treated with primary CMF. Response was assessed by mammography. Disease-free survival (DFS) and overall survival (OS) were calculated after a mean follow-up of 116 months. Statistical analysis was performed to study the association between HER-2/neu status and response to CMF.

Results: Overexpression/amplification was found in 23.66% cases. Univariate analysis showed that response was similar in HER-2/neu positive and negative tumors (51.38 vs. 47.36%, P = 0.6). Triple negative tumors (ER, PR and HER-2/neu negative) presented the highest response rate (64.9%). By multivariate analysis, response was significantly correlated to higher nuclear grade and negative estrogen receptor status (P = 0.02 and 0.007, respectively). Patients with HER-2/neu positive tumors presented shorter survival rates (P = 0.06). Patients with response to CMF showed a better survival over non-responders independent of Her-2/neu status. Patients with the combination of response to CMF and Her-2/neu negative tumors presented the best outcome. On the other hand, the association of no response to CMF and positive Her-2/neu score was statistically related to poor DFS and OS.

Conclusions: CMF indication is independent of Her-2/neu status.

PubMed Disclaimer

Figures

Fig. 1

Response rate according to hormonal receptor and Her-2/neu status

Fig. 2

Disease-free survival (DFS) according to HER-2/neu status. The P values for these two curves are 0.29

Fig. 3

Disease-free of local recurrence (DFS LR) according to HER-2/neu status. The P values for these two curves are 0.22

Fig. 4

Disease-free of local failure (DFS LF) according to HER-2/neu status. The P values for these two curves are 0.04

Fig. 5

Overall survival according to HER-2/neu status. The P values for these two curves are 0.06

Fig. 6

Patients with response to CMF presented a better DFS compared to non-responders regardless of HER-2/neu status

Fig. 7

Patients with response to CMF presented a better OS compared to non-responders regardless of HER-2/neu status

References

1. Allred DC, Clark GM, Tandon AK et al (1992) HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599–605 - PubMed
1. Bargmann CI, Hung MC, Weinberg (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226–230 - DOI - PubMed
1. Baselga J, Seidman AD, Rosen PP et al (1997) HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 11:43–48 - PubMed
1. Bonadonna G, Valagussa P, Brambilla C et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93–100 - PubMed
1. Buchholz TA, Huang EH, Berry D et al (2004) HER2/neu positive disease does not increase risk of locorregional recurrence for patients treated with neoadjuvant doxorrubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 59:1337–1342 - DOI - PubMed

HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy - PubMed (original) (raw)